Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938008 | 1.00 | TP53 (0.36) | TP53TSHRSLC7A5MEN1HPGD | |
| Iodide SCHEMBL5709280 | 0.95 | TP53 (0.33) | TP53TSHR | |
| SCHEMBL28033169 | 0.77 | LMNA (0.33) | TSHR | |
| SCHEMBL11490831 | 0.77 | TSHR (0.31) | TSHR | |
| SCHEMBL11562468 | 0.75 | TP53 (0.42) | TP53TSHRSLC7A5 | |
| SCHEMBL1970742 | 0.73 | SMN1; SMN2 (0.38) | TSHRMEN1KMT2A | |
| SCHEMBL291310 | 0.72 | — | — | |
| SCHEMBL22893306 | 0.72 | — | — | |
| SCHEMBL6896886 | 0.72 | — | — | |
| SCHEMBL668603 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197585-A1 | Use of cysteinyl leukotriene 2 receptor antagonists | EVANS JILLY | 2007-08-23 | — | — | US | disclosed |
| EP-1727533-A1 | USE OF CYSTEINYL LEUKOTRIENE 2 RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005082346-A1 | USE OF CYSTEINYL LEUKOTRIENE 2 RECEPTOR ANTAGONISTS | MERCK & CO, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197585-A1 | Use of cysteinyl leukotriene 2 receptor antagonists | CYSLTR2, CYSLTR1, LTB4R2 | TP53 4240/4885TSHR 402/4885SLC7A5 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.